Article
A Tumultuous Year for Gene Therapy
1 Nov 2000
Abstract excerpt
On September 17, 1999, 18-year-old Jesse Gelsinger died at the University of Pennsylvania following administration of recombinant adenoviral vector containing the orinithine transcarbamylase (OTC) gene. In the decade-old history of nearly 400 clinical gene therapy trials involving well over 4000 patients, Gelsinger's was and still remains the only death directly attributable to gene delivery vehicle. Why, then,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
